Business Context and Reporting Period
Pavmed Inc. (PAVM) filed a Form 8-K on January 15, 2025, reporting the results of a special meeting of stockholders held on the same date. Approximately 53.8% of outstanding shares entitled to vote were present in person or by proxy.
Key Financial Metrics
This filing is a current report regarding corporate governance and capital structure changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these financial indicators.
Material Changes
Stockholders approved three significant proposals at the special meeting:
- Debt-to-Equity Conversion (Proposal 1a): Approved the issuance of common stock upon conversion of Series C Convertible Preferred Stock under a Debt Exchange Agreement dated November 15, 2024. Votes: 5,478,845 For, 458,509 Against, 22,972 Abstain.
- Preferred Stock Issuance (Proposal 1b): Approved the issuance of common stock upon conversion of Series C Preferred Stock under a Securities Purchase Agreement dated November 20, 2024. Votes: 5,462,113 For, 468,387 Against, 29,826 Abstain.
- Authorized Share Increase (Proposal 2): Approved an amendment to the Certificate of Incorporation to increase authorized common stock by 200,000,000 shares, from 50,000,000 to 250,000,000 shares. Votes: 5,227,061 For, 719,044 Against, 14,221 Abstain.
The Certificate of Amendment was filed with the Delaware Secretary of State and became effective on January 15, 2025.
Outlook and Management Commentary
Management expects to consummate the exchange of debt for Series C Preferred Stock and the sale of Series C Preferred Stock as promptly as practicable, and in any event prior to January 31, 2025. The filing incorporates by reference the Definitive Proxy Statement filed on December 6, 2024, for a fuller description of the transactions.
Investor Verification Checklist
- Verify the final closing date of the debt exchange and securities purchase transactions (expected before January 31, 2025).
- Review the Definitive Proxy Statement (Schedule 14A filed December 6, 2024) for detailed terms of the Series C Preferred Stock and the Debt Exchange Agreement.
- Confirm the impact of the 200,000,000 share increase on potential future dilution.
- Check subsequent filings for the actual issuance of common stock resulting from the approved conversions.